Skip to main content
Fig. 6 | Alzheimer's Research & Therapy

Fig. 6

From: Oligomeric tau-targeted immunotherapy in Tg4510 mice

Fig. 6

Treatment with TOMA did not affect levels of tau detected by antibody pSer396 or Gallyas silver staining. Representative sections from nontransgenic mice (a, b), Tg4510 mice treated with IgG (c, d), or Tg4510 mice treated with TOMA (e, f) for the hippocampus. Little staining is detected in the nontransgenic mice (a, b) or Tet mice (data not shown). Immunostaining quantification utilizing Mirax software (Zeiss Inc.) in the anterior cortex (ACX), hippocampus (HPC), and posterior cortex (PCX) of Tg4510 mice treated with IgG1 (black bars) or TOMA (striped bars) (h, i). *p < 0.05. Data presented as mean ± SEM. TOMA tau oligomer monoclonal antibody

Back to article page